L-glutamine improves skeletal muscle cell differentiation and prevents myotube atrophy after cytokine (TNF-α) stress via reduced p38 MAPK signal transduction by Girven, M et al.
This is the peer reviewed version of the following article: Girven M, Dugdale HF, Owens DJ, Hughes DC, Stewart CE & 1 
Sharples AP. (2016). L-glutamine Improves Skeletal Muscle Cell Differentiation and Prevents Myotube Atrophy after 2 
Cytokine (TNF-α) Stress via Reduced p38 MAPK Signal Transduction. Journal of Cellular Physiology, Epub ahead of print, 3 
which has been published in final form at https://dx.doi.org/10.1002/jcp.25380. This article may be used for non-4 
commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving 5 
 6 
L-glutamine improves skeletal muscle cell differentiation and 7 
prevents myotube atrophy after cytokine (TNF-α) stress via 8 
reduced p38 MAPK signal transduction  9 
 10 
Matthew Girven1+ 11 
Hannah F. Dugdale1+ 12 
Daniel J. Owens 1,2 13 
David C. Hughes1,3  14 
Claire E. Stewart1 15 
Adam P. Sharples 1* 16 
 17 
 18 
1 Stem Cells, Ageing and Molecular Physiology Research Unit, Exercise Metabolism and Adaptation Research 19 
Group, Research Institute for Sport and Exercise Sciences (RISES), Liverpool John Moores University, 20 
Liverpool, UK. 21 
 22 
2 Sorbonne Universités, UPMC University of Paris 06, INSERM UMRS974, CNRS FRE3617, Centre de Recherche 23 
en Myologie (CRM), GH Pitié Salpêtrière, Paris 13, France. 24 
 25 
3 Department of Neurobiology, Physiology and Behavior, University of California Davis, Davis, USA. 26 
 27 
Primary Authors + 28 
  29 
* Senior Corresponding Author 30 
  31 
Abstract 32 
Tumour Necrosis Factor- Alpha (TNF-α) is chronically elevated in conditions where skeletal muscle loss occurs. 33 
As L-glutamine can dampen the effects of inflamed environments, we investigated the role of L-glutamine in 34 
both differentiating C2C12 myoblasts and existing myotubes in the absence/presence of TNF-α (20 ng.ml-1) ± L-35 
glutamine (20 mM).TNF-α reduced the proportion of cells in G1 phase, as well as biochemical (CK activity) and 36 
morphological differentiation (myotube number), with corresponding reductions in transcript expression of: 37 
Myogenin, Igf-I and Igfbp5. Furthermore, when administered to mature myotubes, TNF-α induced myotube 38 
loss and atrophy underpinned by reductions in Myogenin, Igf-I, Igfbp2 and glutamine synthetase and parallel 39 
increases in Fox03, Cfos, p53 and Bid gene expression. Investigation of signaling activity suggested that Akt and 40 
ERK1/2 were unchanged, JNK increased (non-significantly) whereas P38 MAPK substantially and significantly 41 
increased in both myoblasts and myotubes in the presence of TNF-α. Importantly, 20 mM L-glutamine reduced 42 
p38 MAPK activity in TNF-α conditions back to control levels, with a corresponding rescue of myoblast 43 
differentiation and a reversal of atrophy in myotubes. L-glutamine resulted in upregulation of genes associated 44 
with growth and survival including; Myogenin, Igf-Ir, Myhc2 & 7, Tnfsfr1b, Adra1d and restored atrophic gene 45 
expression of Fox03 back to baseline in TNF-α conditions. In conclusion, L-glutamine supplementation rescued 46 
suppressed muscle cell differentiation and prevented myotube atrophy in an inflamed environment via 47 
regulation of p38 MAPK. L-glutamine administration could represent an important therapeutic strategy for 48 
reducing muscle loss in catabolic diseases and inflamed ageing.  49 
 50 
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Introduction 71 
 72 
In skeletal muscle tissue, the production of the pleiotropic inflammatory cytokine Tumour Necrosis Factor-Alpha 73 
(TNF-α) via both immune and skeletal muscle cells improves surrounding vascular permeability, aids infiltration 74 
of immune cells from the circulation and facilitates the removal of necrotic tissue after injury and damaging 75 
exercise. Ourselves and others have demonstrated early acute increases in TNF-α are important in skeletal 76 
muscle cell proliferation via activation of the MAPK’s (Al-Shanti et al., 2008; Foulstone et al., 2004; Li, 2003; 77 
Serrano et al., 2008; Sharples et al., 2010; Stewart et al., 2004). Others have also suggested that the acute 78 
production of TNF-α correlates positively with satellite cell activation in-vivo after damaging exercise (Mackey et 79 
al., 2007; Mikkelsen et al., 2009; van de Vyver and Myburgh, 2012). Importantly, chronic TNF-α exposure is 80 
conversely associated with severe muscle cell apoptosis (Foulstone et al., 2001; Grohmann et al., 2005b; 81 
Meadows et al., 2000; Saini et al., 2008; Saini et al., 2012; Saini et al., 2010; Sharples et al., 2010; Stewart et al., 82 
2004), muscle wasting in-vivo (Li et al., 2005; Li and Reid, 2000) and the pathology of cachexia, reviewed in 83 
(Saini et al., 2006). TNF-α is also chronically increased systemically in aged humans (Bruunsgaard et al., 2003a; 84 
Bruunsgaard et al., 2003b; Bruunsgaard and Pedersen, 2003; Greiwe et al., 2001) and the local production by 85 
the muscle is also elevated (Greiwe et al., 2001; Leger et al., 2008), an aetiology that strongly correlates with the 86 
incidence of muscle loss with age (sarcopenia), reviewed in (Saini et al., 2006; Sharples et al., 2015a). This 87 
reduction in muscle mass due to chronically elevated TNF-α can be somewhat attributed to inhibition of muscle 88 
cell differentiation and promotion of myofibre atrophy observed in-vitro and during muscle loss in-vivo (Al-89 
Shanti et al., 2008; Foulstone et al., 2004; Foulstone et al., 2001; Foulstone et al., 2003; Grohmann et al., 90 
2005a; Grohmann et al., 2005b; Jejurikar et al., 2006; Li et al., 2005; Li et al., 2003; Li and Reid, 2000; 91 
Meadows et al., 2000; Saini et al., 2008; Saini et al., 2012; Saini et al., 2010; Sharples et al., 2010; Stewart et al., 92 
2004). Most recent studies by our group also show that skeletal muscle has a memory of acute early life exposure 93 
to TNF-α underpinned by epigenetic retention of DNA methylation over its proliferative lifespan, rendering 94 
skeletal muscle more susceptible to inflamed muscle loss events in later life (Sharples et al., 2015b). Therefore, 95 
understanding how to dampen the impact of chronically elevated inflammatory cytokines in skeletal muscle 96 
across the lifespan is important for future therapies to ameliorate muscle loss.  97 
 98 
Importantly, high TNF-α as a result of surgery, sepsis, burns injury and cancer cachexia (Bode et al., 1996; 99 
Calder and Yaqoob, 1999; Karinch et al., 2001; Labow and Souba, 2000; Parry-Billings et al., 1990; Roth et al., 100 
1982) are associated with large reductions in the amino acid, glutamine, both in the circulation and from skeletal 101 
muscle stores. Glutamine is predominantly synthesized endogenously by skeletal muscle and therefore 102 
traditionally considered a ‘non-essential’ amino acid (Curthoys and Watford, 1995; Watford, 2015). However, 103 
due to its considerable depletion after inflammatory stress, glutamine has been termed a ‘conditionally essential’ 104 
amino acid, as reviewed in (Lacey and Wilmore, 1990). Supplementary glutamine increases muscle protein 105 
synthesis by approximately 10% in rodents after administration of atrophy inducing glucocorticoid, 106 
dexamethasone (Boza et al., 2001), and can help prevent loss of fat free mass in cancer cachexia (May et al., 107 
2002). These data suggest glutamine could be a promising therapy to ameliorate muscle loss in conditions that 108 
are driven by chronic increases in inflammatory cytokines such as TNF-α.  109 
 110 
There are however limited studies into the molecular mechanisms of glutamines action, particularly the 111 
intracellular signaling mechanisms underpinning its positive action in inflamed skeletal muscle. At the cellular 112 
level, glutamine administration has been reported to significantly reduce TNF-α protein levels post 113 
lipopolysaccharide (LPS) administration in human peripheral blood mononuclear cells (PBMCs) (Wischmeyer et 114 
al., 2003). Specifically, in skeletal muscle it has been reported that glutamine was able to restore glucocorticoid 115 
(dexamethasone) induced skeletal muscle atrophy in rat tissue (Salehian et al., 2006). This positive adaptation 116 
with glutamine supplementation was associated with the suppression of myostatin transcription back towards 117 
levels seen in control and glutamine alone groups, as well as a corresponding return of myostatin protein 118 
abundance back towards glutamine only conditions (Salehian et al., 2006). In the same study, these findings 119 
were confirmed in C2C12 myoblasts where in this model the authors demonstrated that myostatin promoter 120 
activity was also suppressed towards baseline in glutamine conditions following an increased activity in the 121 
presence of the catabolic glucocorticoid (Salehian et al., 2006). More recently the findings suggesting a role for 122 
glutamine in modulating myostatin have been translated from glucocorticoids to the inflammatory cytokine 123 
TNF-α; where the treatment of C2C12 myotubes with this cytokine led to increased myostatin protein levels and 124 
myotube atrophy. Importantly again, glutamine was able to return myostatin protein levels back to towards 125 
baseline, albeit not completely restoring them to control levels as well as enabling normal myotube growth 126 
(Bonetto et al., 2011). 127 
 128 
Despite the reported regulation of myostatin by L-glutamine in models of atrophic conditions, there are limited 129 
investigations into the intracellular signaling responses underlying the role of glutamine in the suppression of 130 
muscle loss following inflammation. TNF-α has been reported to strongly up-regulate p38 mitogen-activated 131 
protein kinases (p38 MAPK) demonstrated by ourselves (Grohmann et al., 2005a) and other groups (Alvarez et 132 
al., 2001; Chen et al., 2007; Li et al., 2005; Palacios et al., 2010; Zhan et al., 2007). Importantly, glutamine has 133 
also been shown to regulate p38 MAPK in other models, including; following exercise induced apoptosis in 134 
leukocytes isolated from rats (Lagranha et al., 2007), in PBMC’s derived from a rat model of sepsis (Singleton et 135 
al., 2005), in-vivo (in the lungs of mice) and in alveolar macrophages post LPS administration in vitro (Ko et al., 136 
2009). Combined, this evidence suggests that p38 MAPK could play an important role in reducing skeletal 137 
muscle loss on a background of TNF-α induced inflammation. 138 
 139 
In the present study our objectives were therefore: 1) To assess the effect of glutamine in restoring impaired 140 
differentiation and reducing myotube atrophy observed in conditions of TNF-α induced inflammation and to; 2)  141 
investigate the underlying role of the stress related MAPKs, p38 and JNK (as well as other important associated 142 
kinases ERK1/2 and Akt) and their downstream modulation of gene transcription in controlling skeletal muscle 143 
differentiation and hypertrophy/atrophy in the presence of TNF-α. We hypothesised that: 1) Glutamine would 144 
rescue TNF-α induced impairments in myoblast differentiation in myoblasts, reduce myotube atrophy and 145 
improve myotube survival in existing myotubes and; 2) the stress related MAPK kinase family of signaling 146 
proteins would be partly responsible for co-coordinating these morphological responses via transcriptionally 147 
restoring genes associated with muscle differentiation, survival and myotube hypertrophy/atrophy that were 148 
otherwise impaired in TNF-α conditions.  149 
 150 
Methods 151 
 152 
Cell Culture and treatments 153 
 154 
C2 and C2C12 mouse skeletal myoblasts (Blau et al., 1985; Yaffe and Saxel, 1977), below passage 12, were 155 
employed in these studies. Cells were seeded at 1 × 106 cells in gelatinized T75 flasks in growth medium (GM) 156 
composed of: DMEM plus 10% hi (heat-inactivated) fetal bovine serum, 10% hi newborn calf serum, 2 mM L-157 
glutamine, and 1% penicillin-streptomycin solution and grown to approximately 80% confluency. Following 158 
trypsinisation, 8 × 104 cells.ml-1 in 2 ml GM/well were plated into pre-gelatinized wells of a six well plate and 159 
incubated for 24 hrs. To assess the impact on early differentiation/fusion, C2C12 myoblasts were washed twice 160 
with PBS and transferred to one of  four different dosing conditions: 1) Low serum media/differentiation media 161 
(DM) alone composed of: DMEM plus 2% heat inactivated horse serum, 2 mM L –glutamine, and 1% penicillin-162 
streptomycin solution; 2) DM + TNF-α (TNF-α) at 20 ng.ml-1; 3) DM+ L-glutamine (LG) at 20 mM and finally 163 
4) DM + 20 ng.ml-1 TNF-α  + 20 mM L-glutamine (TNF-α + LG) for up to 72hrs (TNF-α: Merck Millipore, UK). 164 
To further assess the impact on established myotube cultures, C2C12 cells were cultured in DM for 7 days to 165 
induce myotube formation then dosed as above (DM, TNF-α, LG and TNF-α + LG) and cultured for a further 72 166 
hrs (up to a total of 10 days post low serum transfer). We have shown previously that C2C12 myoblasts are 167 
resistant to early cell death following TNF-α administration, whereas parental C2 cells are susceptible to cell 168 
death in these conditions (Sharples et al., 2010). Therefore, in order to assess the impact on early myoblast cell 169 
death, C2 myoblasts were dosed with TNF-α in the absence and presence of LG for 48 hrs and dead cell 170 
percentage was assessed (methods as described below). We have previously used the above doses of TNF-α to 171 
study skeletal muscle apoptosis in murine C2 cells (Foulstone et al., 2001; Saini et al., 2008; Sharples et al., 2010; 172 
Stewart et al., 2004) and human cells (Foulstone et al., 2004). Similar doses have also been used to inhibit 173 
muscle cell differentiation in C2C12 by ourselves and others (Sharples et al., 2010; Tolosa et al., 2005). It is also 174 
worth noting that for most experiments using myoblasts, 2 mM L-glutamine is already present in the 175 
differentiation medium (used in DM control conditions) therefore reductions in differentiation observed with 176 
TNF-α administration occur even in these lower 2 mM L-glutamine concentrations. Therefore, for the purposes 177 
of these experiments LG conditions described above are administered at an additional bolus of 20 mM. Finally, 178 
intravenous (iv.) glutamine administration (o.5 g/kg/bw over 4 hours for three consecutive days) in critically ill 179 
patients has been suggested to elevate circulating levels between 10-50 mM (Berg et al., 2002; Wernerman, 180 
2008), therefore the high dose of LG investigated in the present study is relevant to receiving iv. administration 181 
of glutamine. C2C12 myoblasts undergo spontaneous differentiation into myotubes on serum withdrawal, and do 182 
not require growth factor addition to stimulate the process (Blau et al., 1985; Tollefsen et al., 1989). Time point 183 
zero (DM 0hrs) was defined as 30 minutes subsequent to transferring into DM for transcript and morphological 184 
assessment. For signaling studies in myoblasts/differentiating cells, time point 0 (0hrs) was defined as 185 
immediately post GM removal (and washing with PBS) before dosing conditions were applied. For signaling 186 
studies in differentiated myotubes, time point 0 was defined as immediately post removal of DM at 7 days (and 187 
washing with PBS) before fresh dosing conditions were applied as described above. For p38 MAPK inhibitor 188 
studies SB203580 (Merck Millipore, UK) was administered at concentrations of 5 and 10 µM.  189 
 190 
Cell extractions  191 
 192 
Cells were extracted for total protein assays and CK (creatine kinase) activity (a biochemical marker of myoblast 193 
differentiation) at 0, 48 and 72 hrs in differentiating C2C12 cells. Briefly, cells were washed twice in PBS and 194 
lysed in 200 µl.well-1 of 0.05 M Tris/MES Triton lysis buffer (TMT: 50 mM Tris-MES, pH 7.8, 1% Triton X-100) 195 
and assayed using commercially available BCATM (Pierce, Rockford, IL, U.S.A) and CK activity (Catachem Inc., 196 
Connecticut, N.E, U.S.A) assay kits according to manufacturer’s instructions. The enzymatic activity for CK was 197 
normalised to total protein content. For rt-RT-PCR experiments cells were lysed in 250 - 300 μl/well TRIZOL 198 
reagent (Invitrogen Life Technologies, Carlsbad, CA), the RNA isolated and quantified (see below). Cytometric 199 
Bead Arrays (CBAs) for cell signaling analysis, cells were extracted at 0, 5 min, 15 min, 2 hrs and 24 hrs post 200 
transfer into dosing conditions above. All cell culture experiments were performed on 3 separate occasions and 201 
all assays were performed in duplicate (refer to figure legends for specific information on the different analyses). 202 
 203 
Morphological assessment: Myotube number, diameter and area 204 
 205 
Morphological differentiation was assessed using a cell imaging system at 10 or 20 × magnification for 206 
representative images and morphological counts/analysis respectively (Leica, DMI 6000 B). Images were 207 
subsequently used for quantitative measures of myotube number and area. Light microscope images were 208 
imported into Image J software (Java soft-ware, National Institutes of Health, USA) for analyses. Myotube 209 
numbers were counted per image and global mean ± SD was determined across all images per experimental 210 
condition (a myotube was defined as containing 3+ nuclei encapsulated within cellular structures, to avoid 211 
counting of cells undergoing mitosis). Myotube area (μm2) was determined by carefully tracing around myotube 212 
structures after converting pixel length to μm using Image J software.  213 
 214 
Cell death 215 
 216 
Adherent cells were collected following trypsinisation and pooled with detached cells in the supernatant. The cell 217 
suspension was prepared as a 1:1 dilution in 0.4% trypan blue stain. Samples were loaded into a Neubauer 218 
haemocytometer for viable and dead cell counting.’ Dead cell percentage (%) was calculated as a proportion of 219 
total cell number (viable and dead).  220 
 221 
RNA extraction and analysis 222 
 223 
Extraction of RNA was performed using the TRIzol method, according to the manufacturer’s instructions 224 
(Invitrogen Life Technologies, Carlsbad, CA, USA). RNA concentration and quality were assessed by UV 225 
spectroscopy at 260 and 280 nM using a Biotech Photometer (WPA UV1101, Biochrom, Cambridge, UK) or 226 
Nanodrop spectrophotometer 2000c (Fisher, Rosklide, Denmark). 70 ng RNA was used for each RT-PCR 227 
reaction. 228 
 229 
Primer Design 230 
 231 
Primer sequences (Table 1) were identified using Gene (NCBI, www.ncbi.nlm.nih.gov/gene) and designed using 232 
both web-based OligoPerfectTM Designer (Invitrogen, Carlsbad, CA, USA) and Primer-BLAST (NCBI, 233 
http://www.ncbi.nlm.nih.gov/tools/primer-blast). With the exception of IGF-I mature peptide mRNA primers 234 
that were used in (Yang et al., 1996). Primers were purchased from Sigma (Suffolk, UK) without the requirement 235 
of further purification. Sequence homology (BLAST) searches ensured specificity to ensure the primers matched 236 
the sequence and therefore gene that they were designed for. Three or more GC bases in the last 5 bases at the 3’ 237 
end of the primer were avoided as stronger bonding of G and C bases can cause nonspecific amplification. Primer 238 
sequences were designed to exclude hairpins, self-dimer and cross-dimers. All primers designed were amplified a 239 
product of between 76 - 280 bp% (Table 1.).  240 
  241 
Reverse transcription real-time polymerase chain reaction (rt-RT-PCR) for gene expression and relative data 242 
analysis 243 
 244 
Rt-RT-PCR reactions for DM vs. TNF-α conditions in C2C12 myoblast differentiation were performed using 245 
Power SYBR Green RNA-to-CT 1 step kit (Applied Biosystems, Carlsbad, CA, USA) on a Chromo4 DNA engine 246 
supported by Opticon Monitor version 3.1.32, MJ Geneworks Inc., Bio-Rad Laboratories, Inc., (Hercules, CA, 247 
USA). RT-PCR reactions for TNF-α ± L-glutamine comparisons in differentiated myotubes were performed 248 
using QuantiFast SYBR Green RT-PCR one-step kit on a Rotogene 3000Q (Qiagen, Crawley, UK) supported by 249 
Rotogene software (Hercules, CA, USA). Rt-RT-PCR for both studies was performed as follows: 10min, 50oC 250 
(reverse transcription), 5 min 95oC (initial denaturation and reverse transcriptase inactivation), followed by 40 251 
cycles of: 10secs, 95oC (denaturation), 30secs, 60oC (annealing and extension). Melt-curve analysis was used to 252 
determine and exclude samples with any non-specific amplification or primer/dimer issues. All melt analysis for 253 
the genes of interest produced single peaks indicating amplification of one gene product with no primer dimer 254 
issues. Relative gene expression levels were calculated using the delta delta Ct (ΔΔCt) equation (Schmittgen & 255 
Livak, 2008). Polymerase (RNA) II polypeptide B (Polr2ß/Rp-IIb) was used as the reference gene (this was 256 
highly stable across all conditions with a mean ± SD Ct of 22.5 ± 0.59 (variation 2.69%) for rt-RT-PCR using 257 
Chromo4 for comparisons of DM vs. TNF- α in differentiating myoblasts and with a mean ± SD Ct 16.69 ± 0.72 258 
(variation 4.3%) for rt-RT-PCR on the Rotorgene 3000Q in myotube studies). To directly compare fold changes 259 
between conditions, the 0 hr time point (as defined above for differentiating myoblast and myotube studies) for 260 
C2C12 cells was used as the calibrator condition in the Ct (ΔΔCt) equation.  261 
 262 
Flow cytometry: Cell cycle analysis 263 
 264 
In differentiating myoblasts at 0, 24 & 48 hrs following transfer into DM or DM + TNF-α cells were trypsinised 265 
(200 µl, 0.5% trypsin/0.02% EDTA solution/well) and pooled with detached cells from the conditioned media. 266 
Following centrifugation (10 mins, 300 g at 4ºC), the supernatant was removed, and the pelleted cells vortexed 267 
and fixed in ice cold 75% ethanol (dropwise) and stored for 24 hrs at -20°C. Cells were again centrifuged for 10 268 
minutes at 300 g at 4ºC. The supernatant was removed, and 2 ml PBS added to wash the cells, prior to vortexing 269 
and centrifuging as above (twice). 1.5 ml of the supernatant was removed and the cell pellet vortexed prior to 270 
addition of 50 µl of ribonuclease A (20 μg.ml-1) and incubated at RT for 30 mins 10 µl propidium iodide labeling 271 
buffer (50 µg.ml-1 propidium iodide, 0.1% sodium citrate, 0.3% Nonidet P-40, pH 8.3) was added to each sample 272 
prior to incubation in the dark at 4ºC for 24 hrs before analysis using a Becton Dickinson FACSCalibur flow 273 
cytometer. Data were collected using Cell Quest (Becton Dickinson, Oxford, England) and analysed using 274 
ModfitTM software (Verity Software House, Topsham, ME, USA).   275 
 276 
Flow cytometry: Cytometric Bead Array (CBA) for quantification of phosphorylated proteins 277 
 278 
BD™ Cytometric Bead Array (CBA) enables simultaneous quantification of intracellular phosphorylated 279 
signalling proteins (Manjavachi et al., 2010; Schubert et al., 2009). Assays were performed according to 280 
manufacturer’s instructions. Briefly, cells were washed and lysed on ice (1x lysis buffer provided in the Cell 281 
Signaling Master Buffer Kit (BDTM Cytometric Bead Array (CBA)) prior to boiling. Protein concentrations were 282 
determined as detailed above. Samples were added to the assay diluent provided (15 µg/sample). Standards were 283 
prepared by serially diluting a stock of recombinant protein (50,000 Units/ml) contained in each BD CBA Cell 284 
Signaling Flex Set (separate flex set for phosphorylated proteins of interest: Akt (T308), ERK1/2 (T202/Y204), 285 
p38 MAPK (T180/Y182) and JNK (T183/Y185). For DM vs. TNF-α comparison for Akt, ERK, JNK and p38 four 286 
phosphorylated proteins per sample were analysed simultaneously in the presence of test capture beads. For L-287 
glutamine ± TNF-α comparisons in both myoblasts and myotubes p38 MAPK was performed alone. All samples 288 
were incubated with the test capture beads (3 hrs) and Phycoerythrin (PE -1 hr). The samples were washed and 289 
centrifuged at 300 g for 5 mins. Supernatant was removed and 300 µl of fresh wash buffer was added prior to 290 
resuspension and analyses on a BD FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA) or a BD Accuri 291 
flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). 300 events were captured per analyate per sample 292 
according to manufacturer’s instructions. Data were analyzed using FCAP array software (Hungary Software 293 
Ltd., for BD Biosciences, San Jose, CA, USA). Although changes in total p38 MAPK protein would be unlikely to 294 
change at the time points studied for p38 MAPK activity (i.e.  minutes – hours),  it can be confirmed that there 295 
were no changes in p38 MAPK (alpha or beta) gene expression (primer details in table 1) in any of the above 296 
culture dosing conditions.  297 
 298 
Statistical Analyses  299 
 300 
Statistical analyses and the significance of the data were determined using Minitab version 17. Results are 301 
presented as mean ± standard deviation (SD). For initial TNF-α dosing experiments statistical significance for 302 
interactions between time (varied depending on the analysis undertaken- detailed above) and dose (DM vs. TNF-303 
α) were determined using a two-way Factorial ANOVA. For cell cycle a two-way ANOVE (3 x2) with time (0, 24, 304 
48 hrs) and dose (DM vs. TNF-α). For CK activity (3 x 2 ANOVA) for time (0, 48, 72 hrs) and dose (DM vs. TNF-305 
α). For gene expression in differentiating myoblasts a two-way (2 x 2) factorial ANOVA for time (0, 48 hrs & 72 306 
hrs) and dose (DM vs. TNF-α) was undertaken. Interactions for phosphorylated proteins in differentiating 307 
myoblasts were determined for time (0, 5, 15 mins, 2, 24 hrs) and dose (DM and TNF-α) also using a two-way 308 
(5×2) factorial ANOVA. Post hoc analyses (with Bonferroni correction) were conducted on data where main 309 
effects for time and dose occurred, without a significant interaction between time and dose. If there were 310 
significant interactions present, t-tests were conducted to confirm statistical significance between the variable of 311 
interest e.g. between doses and/or time. For glutamine experiments; phosphorylated protein analysis was 312 
conducted using a 2 way (2 x 4) Factorial ANOVA for time (15 mins vs. 2hrs) and dose (DM, TNF-α, LG, LG + 313 
TNF-α) and post hoc (with Bonferroni correction) tests conducted for pairwise comparisons. Morphological 314 
analysis for glutamine experiments (myotube number and area) were performed at either 72 hrs in 315 
differentiating myoblasts or at +72 hrs (10 days total as described above) in differentiated myotubes using a one-316 
way ANOVA  for dose (DM, TNF-α, LG, LG + TNF-α). Glutamine experiments for gene expression in myotube 317 
cultures were analyzed using a one-way ANOVA for dose (DM, TNF-α, LG, LG + TNF-α). Fisher LSD post hoc 318 
tests were conducted for pairwise comparisons following one-way ANOVA’s. For all statistical analyses, 319 
significance was accepted at P ≤ 0.05.  320 
 321 
Results 322 
 323 
TNF-α reduces early myoblast fusion and myotube formation in differentiating myoblasts  324 
 325 
Fusion and myotube number were reduced in early differentiating C2C12 cells in the presence of TNF-α (Figure 326 
1). As G1 cell cycle exit is a prerequisite for myoblast differentiation we observed that there was a significant 327 
decrease in the proportion of cells in the G1 phase at 24 hrs following the induction of differentiation following 328 
serum withdrawal and TNF-α administration (CON DM 82.96 ± 1.01 vs. TNF-α 71.23 ± 0.3% at 24 hrs, P ≤ 329 
0.001; Figure 1A) and a relative increase in S/G2 phase (data not included), suggesting a shift from 330 
differentiation to continued cellular division. Biochemical analyses of differentiation at the later time-points of 331 
48 and 72 hrs following serum withdrawal subsequently confirmed the cell cycle differences, where it was 332 
observed that compared with control, there were significant reductions in CK activity in TNF-α conditions (DM 333 
342 ± 46 vs. TNF-α 189 ± 38 mU.mg.ml-1 at 48 hrs; DM 492 ± 36 vs. TNF-α 274 ± 68.3 mU.mg.ml-1 at 72 hrs; 334 
both P ≤ 0.001; Figure 1B). Overall this resulted in a significant impact on cellular morphology shown by a 335 
reduction in myotube number (DM 2.39 ± 0.58 vs. TNF-α 1.31 ± 0.48; P ≤ 0.001, Figure 1C and 1G) at 72 hrs in 336 
the presence of TNF-α. To confirm cell cycle, biochemical and morphological data at the molecular level we 337 
investigated gene transcription of Myogenin (an important myogenic regulator factor) and insulin-like growth 338 
factor family members (Igf-I, Igf-Ir, Igfbp5, Igfbp2) involved in fusion and myotube formation in differentiating 339 
myoblasts. Myogenin decreased in myoblasts in the presence of TNF-α at 48 hrs by 2.45 fold (DM 70.4 ± 11.2 vs. 340 
TNF-α 28.69 ± 5.35 P ≤ 0.001; Figure 1D). A similar trend was observed at 72 hrs for Igf-I expression with a near 341 
2 fold average reduction following TNF-α administration (DM 86.9 ± 24.7 vs. TNF-α 44 ± 18.3, P ≤ 0.001; Figure 342 
1E). Igf-Ir was unchanged with the addition of TNF-α (data not shown). Due to reductions in Igf-I, IGF binding 343 
proteins 2 and 5 that modulate the binding of IGFs to their receptors and regulate myoblast differentiation 344 
(Foulstone et al., 2001; Meadows et al., 2000; Sharples et al., 2013) were assessed. Indeed, in the presence of 345 
TNF-α there was a decline in IGFBP5 expression at 72 hrs by 1.87 fold (DM 3.74 ± 1.39 vs. TNF-α 2 ± 0.35, P = 346 
0.03); Figure 1F), there were however no significant differences in IGFBP2 expression following TNF-α exposure 347 
(data not shown).   348 
 349 
 350 
TNF-α evokes a loss of myotubes and myotube atrophy in existing differentiated myotubes. 351 
  352 
When TNF-α was administered to existing myotubes the cytokine significantly reduced myotube survival shown 353 
via reductions in myotube number (DM 9.63 ± 3.98 vs. TNF-α 6.15 ± 2.5, P ≤ 0.05; Figure 2A). Furthermore, in 354 
the myotubes that did survive, compared with controls, atrophy occurred as evidenced by significant reductions 355 
in myotube area in the presence of TNF-α (DM 8305 ± 4676 vs. TNF-α 5557 ± 2810 µm2, P ≤ 0.001; Figure 2B). 356 
In order to investigate the molecular regulators of these processes in differentiated myotubes we investigated the 357 
transcript expression in response to TNF-α administration for a range of genes important in myotube maturation 358 
and growth (Myogenin, Myomaker, Mrf4, Myhc’s 1, 2, 4 & 7, Igf-I, Igf-Ir, Igfbp2), atrophy (Myostatin, Musa1, 359 
Murf-1, Mafbx, Nf- κb, Tnf-α, both Fox01 & Fox03), apoptosis/survival (Tnfrsf1a & b, Cfos, Cmyc, p53, Bid, Bad, 360 
Bax, Adra1d, Sirt1) and glutamine synthesis (glutamine synthetase). Seventy two hrs post TNF-α administration 361 
to existing myotubes, there were significant reductions in genes associated with myotube maturation and 362 
growth. There was an average 2.95 fold reduction in myogenin (DM 0.59 ± 0.29 vs. TNF-α 0.2 ± 0.04; P = N.S, 363 
Figure 2C), as well as a significant, almost 10 fold reduction in Igf-I (DM 0.84 ± 0.49 vs. TNF-α 0.09 ± 0.02, P = 364 
0.02, Figure 2D), with corresponding reductions for Igfbp2 (2 fold) (DM 0.98 ± 0.33 vs. TNF-α 0.48 ± 0.06, P = 365 
0.007, Figure 2E). Furthermore, TNF-α significantly increased transcription of genes involved in skeletal muscle 366 
atrophy including a 2.65 fold increase in Fox03 (DM 1.0 ± 0.47 vs. TNF-α 2.65 ± 0.15, P = 0.002, Figure 2F), as 367 
well as corresponding increases in cell death/survival genes; p53 by 1.78 fold (DM 1.0 ± 0.334 vs. TNF-α 1.78 ± 368 
0.16, P = 0.001, Figure 2H), and Cfos by 3 fold (DM 0.37 ± 0.14 vs. TNF-α 1.14 ± 0.13 P ≤ 0.001, Figure 2I). A 2.2 369 
fold increase was observed for Bid mRNA (DM 1.24 ± 0.15 vs. TNF-α 2.73 ± 0.39, P = 0.003, Figure 2J) in the 370 
presence of TNF-α. Finally, glutamine synthetase reduced 2 fold in the present of TNF-α (DM 0.96 ± 0.09 vs. 371 
TNF-α 0.45 ± 0.03, P = 0.002, Figure not shown). It is worth noting that we observed no significant differences 372 
in the remaining genes investigated (above) including those previously associated with elevated TNF-α e.g.  Nf- 373 
κb (DM 0.24 ±0.18 vs. TNF-α 0.48 ± 0.06), Tnf-α (DM 0.96 ± 0.44, TNF-α 0.72 ± 0.17), myostatin (DM 1.53 ± 374 
0.51, TNF-α 1.54 ± 0.07), Mafbx (DM 0.78 ± 0.4, TNF-α 1.2 ± 0.50), Murf-1 (DM 0.97 ± 0.16, TNF-α 1.07 ± 375 
0.09) and Fox01 (DM 0.73 ± 0.24, TNF-α 0.72 ± 0.04,) all comparisons,  P = N.S. 376 
Early increases in phosphorylated p38 MAPK but not JNK, AKT or ERK1/2 in the presence of TNF- α are 377 
associated with reductions in myoblast differentiation, myotube formation and increased atrophy. 378 
 379 
It has previously been observed that the MAPK and PI3K pathways regulate proliferation and differentiation 380 
(Coolican et al., 1997) as well as survival basally (Stewart et al., 1999) and in the presence of TNF-α (Al-Shanti et 381 
al., 2008; Foulstone et al., 2001). We therefore hypothesized that these pathways were important for the 382 
morphological adaptation and gene expression patterns described above. There was however, no impact of TNF-383 
α on ERK1/2 or Akt activity over 24 hours (analyses conducted at 0, 5, 15 mins, 2hrs, 24 hrs) in myoblasts (data 384 
not shown). While there was a mean increase in JNK1/2 activity at 15 mins this did not reach significance (Figure 385 
3A), however p38 MAPK activation over 24 hrs (analysis conducted at 0, 5, 15 mins, 2hrs, 24 hrs; Figure 3B) was 386 
significantly increased at 15 mins after transferring into DM vs. DM + TNF-α (DM 93.5 ± 25.6 vs. TNF-α 173.8 ± 387 
35 units.ml-1, P = 0.014; Figure 3B). Overall suggesting early p38 MAPK activity may be important in the TNF-α 388 
induced reduction in early differentiation. We subsequently confirmed that p38 MAPK increased at the same 389 
time point 15 mins in differentiated myotubes (DM 11.43 ± 4.69 vs. TNF-α 69.18 ± 3.99 units.ml-1, P ≤ 0.001; 390 
Figure 3C), indicating that p38 MAPK activity was also important in the TNF-induced myotube atrophy. 391 
L-glutamine reduced p38 MAPK activity, rescued myotube atrophy in the presence of TNF-α via reduced 392 
atrophic (Fox03) and increased muscle growth (Igf-Ir), myotube maturation (Myhc 2 & 7) and survival 393 
(Tnfrsf1b and Adrad1) gene expression. 394 
In differentiating myoblasts at 15 mins, L-glutamine alone was sufficient to significantly reduce the activity of 395 
p38 MAPK vs. control DM conditions (DM 90.13 ± 11.85 vs. LG 25.46 ± 7.96, P ≤ 0.05, Figure 4A), importantly 396 
L-glutamine also reduced p38 MAPK activity in TNF-α conditions at this time point in differentiating myoblasts 397 
(LG + TNF-α 69.93 ± 25.71 vs. TNF-α 155.88 ± 34.98, P ≤ 0.01; vs. DM 90.13 ± 11.85, P = N.S; vs. LG alone 398 
25.46 ± 7.96, P = N.S, Figure 4A). In differentiated myotubes on a background of TNF-α, L-glutamine was also 399 
able to return the high activity levels observed in TNF-α conditions back to baseline DM values (LG + TNF-α 400 
24.14 ± 14.4 vs. TNF-α 69.18 ± 3.99, P ≤ 0.001; vs. DM 11.42 ± 4.69, P = N.S; vs. LG alone 16.89 ± 8.83 units.ml-401 
1, P = N.S, Figure 4B). It is worth noting that p38 MAPK inhibitor (SB203580) was unable to attenuate the 402 
negative alterations in myotube morphology following TNF-α administration (data not shown).  403 
L-glutamine was also able to improve myotube number back towards baseline in the presence of TNF-α (LG + 404 
TNF-α 1.94 ±  0.49 vs. TNF-α 1.31 ± 0.48, P ≤ 0.03; vs. DM 2.39 ± 0.58, P = N.S; vs. LG alone 2.45 ± 0.61, P = 405 
N.S, Figure 5A) in existing myotubes L-glutamine on average reduced the myotube number observed in TNF-α 406 
conditions although this was not significant (LG + TNF-α 7.37 ± 2.45 vs. TNF-α 6.15 ± 2.52, P = 0.147; vs. DM 407 
9.63 ± 3.98, P = 0.008; vs. LG alone 8.67 ± 3.076, P = N.S, Figure 5B) and importantly helped prevent myotube 408 
atrophy in existing myotubes in the presence of TNF-α (area LG + TNF-α 7576 ± 3792  vs. TNF-α 5557 ± 2810, P 409 
≤ 0.001; vs. DM 7949 ± 4730, P = N.S; vs. LG alone 9063 ± 4669 µm2, P ≤ 0.003, Figure 5C). Glutamine was 410 
however unable to significantly reduce dead cell percentage in the presence of TNF-α in parental C2 myoblasts at 411 
48hrs (TNF-α 27 ± 9% vs. TNF + LG 23 ± 10%, P = N.S.). As there was extensive impact of TNF-α on myotube 412 
atrophy when administered to existing myotubes, we investigated the downstream transcriptional targets of 413 
increased p38 MAPK signaling post rescue with L-glutamine for an array of genes involved in myotube 414 
maturation and growth (Myogenin, Myomaker, Mrf4, Myhc’s 1, 2, 4 & 7, Igf-I, Igf-IR, Igfbp2), atrophy 415 
(Myostatin, Musa1, Murf-1, Mafbx, Nf- κb, Tnf-α, Fox01, Fox03), apoptosis and survival (Tnfrsf1a & b, Cfos, 416 
Cmyc, p53, Bid, Bad, Bax, Adra1d, Sirt1) and glutamine synthesis (glutamine synthetase). Importantly, L-417 
glutamine administration in response to TNF-α administration led to a dramatic 10 fold upregulation of 418 
Myogenin versus TNF-α alone (Figure5A) (LG + TNF-α 2.7 ± 1.36 vs. TNF-α 0.2 ± 0.04, P = 0.002; Figure 6A) 419 
resulting in significantly higher expression versus baseline (LG + TNF-α 2.7 ± 1.36 vs. DM 0.56 ± 0.29, P = 420 
0.006; Figure 6A) and L-glutamine alone conditions (LG + TNF-α 2.7 ± 1.36  vs. LG 0.2 ± 0.08, P = 0.002). 421 
Similar trends were observed for Igf-Ir gene expression where a 4 fold increase was observed in LG + TNF-α vs. 422 
TNF-α alone (LG + TNF-α 2.62 ± 0.91 vs. TNF-α 0.64 ± 0.24, P ≤ 0.001; Figure 6B) with significantly higher 423 
expression than that seen at baseline and vs. L-glutamine alone treatments (LG + TNF-α 2.62 ± 0.91 ±  vs. DM 424 
0.51 ± 0.26, P ≤ 0.001; vs. LG 0.39 ± 0.07, P ≤ 0.001; Figure 6B). The same trend was mirrored for: Myhc2 with 425 
an almost 3 fold increase (LG + TNF-α 5.69 ± 2.71 vs. TNF-α 1.94 ± 0.264, P = 0.01; vs. DM 1.458 ± 0.473, P = 426 
0.006;  vs. LG alone 1.22 ± 0.06, P = 0.004; Figure 6C), an 8.2 fold increase in Myhc7 (LG + TNF-α 6.45 ±  0.47 427 
vs. TNF-α 0.79 ± 0.23, P ≤ 0.001; vs. DM 0.82 ± 0.41, P ≤ 0.001; ±vs. LG alone 0.66 ± 0.2, P ≤ 0.001; Figure 428 
6D), as well as a 5.4 fold increase in Tnfrsf1b (LG + TNF-α 2.88 ± 2.09 vs. TNF-α 0.53 ± 0.09, P = 0.025; vs. DM 429 
0.43 ± 0.14, P = 0.021; vs. LG alone 0.4 ± 0.11, P = 0.02; Figure 6E), and finally an 2.7 fold increase in Adrad1 430 
(LG + TNF-α 0.83 ± 0.08 vs. TNF-α 0.31 ± 0.05, P ≤ 0.001; vs. DM 0.42 ± 0.15, P = 0.002; vs. LG alone 0.28 ± 431 
0.11, P ≤ 0.001; Figure 6F). Importantly, in the presence of TNF-α L-glutamine was also able to significantly 432 
downregulate transcriptional target Foxa3a from 2.65 fold in TNF-α conditions (described above) down to 1.87 433 
fold (LG + TNF-α 1.87 ± 0.33 vs. TNF-α 2.65 ± 0.15, P = 0.05 Figure 6G) returning them back to baseline and LG 434 
alone levels (LG + TNF-α 1.87 ± 0.33 vs. DM 1.0 ± .047, P = 0.038, vs. LG alone 1.64 ± 0.62, P = N.S). Results for 435 
p53 were somewhat similar, where L-glutamine was able to return 1.78 fold increases above baseline observed in 436 
TNF-α conditions to 1.53 fold increases above baseline, despite this LG + TNF-α was not significantly different to 437 
TNF- α alone  (LG + TNF-α 1.56 ± 0.08 vs. TNF-α 1.78 ± 0.16, P = N.S; Figure 6H) and was still significantly 438 
elevated above baseline/DM (LG + TNF-α 1.56 ± 0.08 vs. DM 1.0 ± 0.33, P = 0.001; Figure 6H) Finally, 439 
following a 3 fold increase in Cfos post TNF administration, L-glutamine was able to reduce this increase vs. 440 
baseline to 2.64 fold, however this did not result in significance vs. TNF-α alone conditions (LG + TNF-α 0.98 ± 441 
0.16 vs. TNF-α 1.14 ± 0.13, P = N.S, vs. baseline DM 0.37 ± 0.14, P ≤ 0.001; Figure 6I). L-glutamine was unable 442 
to return the 2.2 fold increase in Bid mRNA described above post TNF-α administration, where levels were the 443 
same when dosed with LG + TNF-α (2.85 ± 0.4 vs. TNF-α alone 2.73 ± 0.4, P = N.S; Figure not shown). Finally, 444 
LG alone conditions resulted in no change in glutamine synthetase (DM 0.96 ± 0.09 vs. LG alone 1.07  ± 0.27, P 445 
= N.S; figure not shown), furthermore, LG was unable to return the reduced levels of glutamine synthetase in 446 
TNF-α conditions back to baseline (0.38 ± 0.12 vs. TNF-α alone 0.45 ± 0.03, P = N.S; figure not shown). Overall 447 
L-glutamine reduced transcript expression of genes that were otherwise increased post TNF-α administration 448 
alone, where p53 and Cfos where partly returned back towards baseline (e.g p53, cfos) yet were non-significant, 449 
importantly howver Fox03 significantly returned back to baseline levels. Furthermore, in the presence of TNF-α, 450 
L-glutamine drove large increases in genes associated with myotoube formation (myogenin) muscle growth (Igf-451 
Ir), myotube maturation (Myhc 2 & 7) and survival (Tnfrsf1b and Adrad1). As these were not significantly 452 
reduced with TNF-α vs. baseline, it suggests L-glutamine was driving these increases in transcription rather than 453 
as simply a compensatory mechanism following TNF-α induced reductions. It is worth noting that we observed 454 
no significant differences in the remaining genes investigated (above) including those previously associated with 455 
elevated L-glutamine e.g. Tnf-α (DM 0.96 ± 0.44, LG 0.55 ± 0.06, TNF-α 0.72 ± 0.17, LG + TNF-α 1.2 ± 0.67) 456 
and myostatin (DM 1.53 ± 0.51, LG 1.42 ± 0.08, TNF-α 1.54 ± 0.07, LG + TNF-α 1.47 ± 0.12). All comparisons P 457 
= N.S. 458 
 459 
Discussion 460 
In the present study we aimed to assess the effect of L-glutamines role in restoring the impaired fusion and 461 
myotube atrophy observed in the presence of TNF-α; as well as the underlying role of the MAPK’s (ERK1/2, p38 462 
and JNK) and associated signalling (Akt) in their downstream modulation of gene transcription involved in 463 
skeletal muscle cell differentiation, myotube growth and survival. We were able to accept our original hypotheses 464 
whereby we demonstrated that; 1) L-glutamine rescued myoblast differentiation and reduced myotube atrophy 465 
in the presence of TNF-α, and that; 2) p38 MAPK kinase (but not JNK, ERK1/2 or Akt) was responsible for 466 
coordinating these morphological responses via transcriptionally restoring some of the important genes 467 
associated with survival and myotube atrophy, particularly Fox03a back to baseline post TNF-α exposure, as well 468 
driving extensive upregulation of Myogenin, Igf-Ir, Myhc2 & 7, Tnfsfr1b, Adrad1 to enable normal 469 
differentiation, myotube growth and survival. 470 
 471 
The findings in the present study investigating the impact of TNF-α on skeletal muscle cell differentiation and 472 
hypertrophy/atrophy correspond with previous studies, whereby after 3 days post serum withdrawal, TNF-α 473 
administration reduces differentiation in myoblasts and results in myotube atrophy when administered to 474 
existing myotubes (Al-Shanti et al., 2008; Foulstone et al., 2004; Foulstone et al., 2001; Foulstone et al., 2003; 475 
Grohmann et al., 2005a; Grohmann et al., 2005b; Jejurikar et al., 2006; Li et al., 2005; Li et al., 2003; Li and 476 
Reid, 2000; Meadows et al., 2000; Saini et al., 2008; Saini et al., 2012; Saini et al., 2010; Sharples et al., 2010; 477 
Stewart et al., 2004). Importantly, we report for the first time that L-glutamine rescued differentiation in 478 
myoblasts in the presence of TNF-α and confirmed previous findings for the role of L-glutamine in rescuing 479 
myotube atrophy in existing myotubes in the presence of TNF-α (Karinch et al., 2001). Interestingly, Akt and 480 
ERK1/2 activity were unchanged in the presence of TNF-α, although JNK activation increased on average with 481 
TNF-α exposure at 15 mins this did not attain significance. These signaling studies confirmed previous findings 482 
where the presence of ERK (PD98059) and JNK (SP60012) inhibitors were unable to ameliorate the negative 483 
impact of TNF-α on protein degradative pathways in skeletal muscle cells (Li et al., 2005). Importantly however, 484 
stress related p38 MAPK activity substantially and significantly increased after 15 mins in the presence of TNF-α 485 
in both differentiating myoblasts and differentiated myotubes, a finding supported in previous studies (Alvarez 486 
et al., 2001; Chen et al., 2007; Grohmann et al., 2005b; Li et al., 2005; Palacios et al., 2010; Zhan et al., 2007). 487 
Importantly, we report for the first time that a bolus (20 mM) of L-glutamine reduced p38 MAPK activity in 488 
TNF-α conditions in both differentiating myoblasts and differentiated myotubes; a signaling response that 489 
corresponded with the ability of L-glutamine to improve fusion of myoblasts and also retain myotube  area in the 490 
presence of TNF-α in already differentiated myotubes. Therefore, the results from this study point to an 491 
important role for L-glutamine in regulating p38 MAPK in the presence of TNF-α.  492 
 493 
In inflammatory conditions p38 MAPK has previously been shown to be activated and involved in culminating in 494 
protein degradation in skeletal muscle (Kim et al., 2009; Li et al., 2003; Li and Reid, 2000; Philip et al., 2005). 495 
However, in basal or healthy conditions p38 MAPK has also been shown to have a positive role in skeletal muscle 496 
cell differentiation, whereby studies adding p38 MAPK inhibitor (SB203580) to myoblasts inhibited 497 
differentiation of C2C12 cells (Li et al., 2000), and more recently we have reported that the MEK inhibitor 498 
PD98059 (that blocks ERK1/2) enhances C2 myoblast differentiation with corresponding increases in 499 
phosphorylated p38 MAPK (Al-Shanti and Stewart, 2008). Therefore, p38 MAPK may have positive or negative 500 
roles in myoblast differentiation depending upon the inflammatory context of the cells. p38-α MAPK has also 501 
been linked to myoD, whereby it phosphorylates MEF2 proteins (Molkentin et al., 1995) which in turn 502 
phosphorylate E47 promoting its heterodimerisation with myoD (Lluis et al., 2005), this then results in muscle 503 
specific transcription such as myogenin gene expression (Keren et al., 2006). It has also been demonstrated that 504 
a different p38 MAPK family member, p38-γ, also plays a crucial role in regulating skeletal muscle 505 
differentiation (Gillespie et al., 2009; Lassar, 2009). In the present study, p38 MAPK phosphorylation (specific 506 
isoforms not distinguished) was elevated in TNF-α treated conditions where impaired differentiation and 507 
myotube atrophy were observed, whereas P38 activity was suppressed in L-glutamine conditions where 508 
differentiation and myotube atrophy were restored in the presence if TNF-α. This suggests that p38 MAPK is 509 
activated via stress related inflammatory mechanisms in the present study. However, it is worth noting that L-510 
glutamine drove significant 10 fold increases in myogenin gene expression even in the presence of TNF-α, 511 
despite reductions in p38 MAPK, that while perhaps enabling a compensatory drive in differentiation following 512 
lack of fusion at earlier time points in the differentiation program (Berkes and Tapscott, 2005), suggests that the 513 
increase in myogenin expression was not regulated by the p38 MAPK/MEF2/myoD/myogenin mechanism 514 
described above. Furthermore, inhibition of p38 MAPK using chemical inhibitor SB203580 in the present study 515 
was unable to rescue the TNF-α induced reductions myotube morphology, this may be due to its apparent 516 
bimodal functions described above as it may be difficult to recover differentiation in the presence of TNF-α 517 
without affecting its role in positively regulating differentiation.  518 
 519 
Unlike previous studies, showing that TNF-α in C2C12 myotubes led to increased myostatin protein levels, that 520 
were also returned following L-glutamine administration (Karinch et al., 2001), the present study saw no change 521 
in myostatin, albeit at the mRNA level, in both TNF-α alone conditions and when the cytokine was co-522 
administered with L-glutamine. Following TNF-α induced increases in p38 MAPK signaling, we did however see 523 
a large increase in Fox03 gene expression, that at the protein level is an important transcription factor in 524 
regulating muscle protein degradation via upregulation of the ubiquitin ligases (Edstrom et al., 2006; Sandri, 525 
2008; Sandri et al., 2004). Despite this, we found no changes in gene expression of the ubiquitin ligases/protein 526 
degradative markers; Atrogin-1 or Mafbx in the presence of TNF-α in myotubes, previously reported to be 527 
transcriptionally regulated by p38 MAPK and correspond with muscle protein degradation (Kim et al., 2009; Li 528 
et al., 2005); perhaps suggesting that future studies should investigate the temporal regulation of these genes to 529 
fully elucidate their role. Importantly however, we were able to demonstrate novel findings that L-glutamine 530 
reduced a TNF-α induced increase in Fox03 back to control conditions. It worth mentioning here that class I 531 
Histone Deactylases (Hdac 1-3 and 8) have been associated with increases in Fox03 and atrophy in skeletal 532 
muscle during nutrient deprivation and disuse induced atrophy (Beharry et al., 2014), and therefore require 533 
further investigation with TNF-α in the current model. Fox0’s have also been reported to promote cell apoptosis, 534 
shifting cellular function towards oxidative stress resistance/detoxification and DNA repair (Brunet et al., 2004; 535 
Greer and Brunet, 2005; Wang et al., 2007). We observed average increases in survival of myotubes and a a 536 
restoration of myotube size in L-glutamine conditions on a background of elevated myotube loss and atrophy, 537 
post TNF-α exposure, perhaps suggesting a key role for Fox03 in this process. Further, as TNF-α has been shown 538 
to increase oxidative stress via elevating reactive oxygen species in skeletal muscle (Reid and Li, 2001), although 539 
requiring confirmation, L-glutamine could also be serving to reduce Fox03 in order to provide reactive oxygen 540 
species detoxification to encourage myotube survival and growth. Another noteworthy finding is that L-541 
glutamine extensively upregulated Myhc 2 & 7 gene expression, coding for slow type I and intermediate type IIa 542 
myofibrillar proteins respectively involved in laying down contractile proteins to prevent myotube atrophy. 543 
Furthermore, the rescue of myotube atrophy post TNF-α exposure by L-glutamine administration substantially 544 
increased the gene expression of Myogenin, Igf-Ir, Tnfsfr1b and Adra1d. As mentioned above the 10 fold 545 
induced increase in Myogenin following L-glutamine administration suggests that the non-essential amino acid 546 
may enable a compensatory drive in differentiation following for lack of fusion at earlier time points (Berkes and 547 
Tapscott, 2005) despite the presence of a potent inhibitor of these processes (TNF-α). In addition to increased 548 
Myhc 2 & 7 and myogenin, following L-glutamine supplementation in the presence of inflammation, an increase 549 
in Igf-Ir was observed and could therefore serve as a feedback mechanism following low Igf-I expression in TNF-550 
α alone conditions (that were not rescued with L-glutamine). Where an increase in Igf-Ir may act as a drive to 551 
enable IGF-I binding to its receptor on a background of low IGF-I ligand; a process we have previously observed 552 
in the presence of TNF-α in C2C12 cells, where a background of impaired Igf-I expression led to compensatory 553 
elevations in Igf-Ir expression (Sharples et al., 2010). Supporting these processes further, the large increase in 554 
Tnfrsf1b gene expression in L-glutamine conditions with exogenous TNF-α may serve to dampen the impact of 555 
TNF-α. This is because this TNF receptor can be liberated from the cell surface and represents an important 556 
mechanism of negative regulation for the biological activity of soluble TNF-α (Bemelmans et al., 1996a; 557 
Bemelmans et al., 1996b), via inactivating and clearing TNF-α. This process of liberated vs. membrane bound 558 
receptor is controlled by TNF converting enzyme (TACE). TACE would increase abundance of cleaved soluble 559 
receptor in the medium and would therefore enable the increase in Tnfrsf1b observed in the present study post 560 
L-glutamine administration to liberate and clear the excess TNF-α, warranting further investigation. Finally, we 561 
have previously seen that Adra1d was elevated following incubations that induced myoblast survival (co-562 
incubations of IGF-I with TNF-α) (Saini et al., 2010). Subsequently, Adra1d knockdown resulted in significantly 563 
higher levels of cell death under TNF-α administration suggesting Adra1d expression is essential for skeletal 564 
muscle cell survival (Saini et al., 2010). A similar role here could be extrapolated to myotubes in the present 565 
study, where with TNF-α exposure Adra1d is elevated to evoke myotube survival when elevated L-glutamine is 566 
available. 567 
 568 
In conclusion for the first time we indicate that L-glutamine suppressed a TNF-α induced increase in stress 569 
related p38 MAPK activity and enabled a restoration of Fox03 gene expression levels back toward baseline post 570 
TNF-α addition, as well as driving extensive upregulation of Myogenin, Igf-Ir, Myhc2 & 7, Tnfsfr1b, Adrad1 to 571 
enable normal myotube growth and survival. Overall, L-glutamine supplementation is important in reducing the 572 
suppression of muscle differentiation and in restoring atrophic myotube phenotypes in inflamed environments.  573 
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Figure 1: Three days post induction of differentiation via serum withdrawal, TNF-α (20 ng.ml-1) 829 
administration reduced the proportion of cells in the G1 phase of the cell cycle at 24hrs (1A), a 830 
prerequisite for myoblast differentiation, as well as later (48 & 72hrs) reductions in biochemical 831 
(CK activity- 1B) and morphological differentiation (myotube number at 72hrs- 1C). This 832 
corresponded with significant reductions in the transcript expression of important myogenic and 833 
growth related genes; Myogenin (1D), Igf-I(1E) and Igfbp5 (1F). Representative morphological 834 
images (20X) for DM vs. TNF-α conditions can be observed in figure 1G. All experiments were 835 
conducted on 3 separate occasions (n = 3); 4-5 morphological images per condition in duplicate 836 
were analyzed for each n.  RT-PCR assays were performed in duplicate. * Significantly different vs. 837 
DM. 838 
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Figure 2: After 3 days of TNF-α administration to existing myotubes, TNF-α induced myotube 864 
loss and atrophy demonstrated via a loss in myotube number (2A) and area (2B). Representative 865 
morphological images (10x) of DM vs. TNF-α can been seen in figure 2C. This was underpinned by 866 
reductions in transcript expression of genes involved in myotube growth; Myogenin (2D), Igf-I 867 
(2E), and Igfbp2 (2F) and an increase in those related to atrophy (Fox03- 2G) and 868 
apoptosis/survival; p53 (2H), cfos (2I), Bid (2J). All experiments were conducted on 3 separate 869 
occasions (n = 3); 4-5 morphological images per condition in duplicate were analyzed for each n.  870 
RT-PCR assays were performed in duplicate. * Significantly different vs. DM.  871 
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Figure 3: In order to investigate the underlying mechanisms of TNF-α’s detrimental impact on 883 
myoblast/myotube morphology (observed in Figure 1 & 2), we investigated the earlier signaling 884 
responses. JNK activity was non-significant (3A), whereas P38 MAPK substantially and 885 
significantly increased its activity after 15 minutes in the presence of TNF-α in differentiating 886 
myoblasts (3B) and differentiated myotubes (3C) vs. baseline. All experiments were conducted on 887 
3 separate occasions (n = 3). CBA array assays were conducted in duplicate. * Significantly 888 
different vs. DM. 889 
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Figure 4: L-glutamine reduced p38 MAPK activity in TNF-α conditions back to control levels in 928 
both differentiating myoblasts (4A) and differentiated myotubes (4B). All experiments were 929 
conducted on 3 separate occasions (n = 3). CBA array assays were conducted in duplicate. * 930 
Significantly different to DM. # Significantly different vs. TNF-α. 931 
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Figure 5: L-glutamine restored morphological measures of myotube formation in differentiating 951 
myoblasts (myotube number 5A), helped somewhat retain myotube number (although non-952 
significant) (5B) and prevented myotube area losses (5C) in myotubes following TNF-α 953 
administration. Representative morphological images (10X) can be seen for TNF-α vs. L-glutamine 954 
(LG) + TNF-α conditions. All experiments were conducted on 3 separate occasions (n = 3); 4-5 955 
morphological images per condition in duplicate were analyzed for each n.  * Significantly different 956 
vs. TNF-α conditions.  957 
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Figure 6: The signaling events (figure 4) and morphological adaptations (figure 5)  in response to 969 
L-glutamine on a background of elevated TNF-α were driven by extensive upregulation of genes 970 
associated with growth and survival including; Myogenin (6A), Igf-Ir (6B), Myhc2 (6C) & 7 (6D), 971 
Tnfsfr1b (6E) Adra1d (6F) and transcriptionally restoring some of the important genes associated 972 
with cell death and myotube atrophy, particularly Fox03 back to baseline (6G) as well as average 973 
reductions (yet non-significant) for p53 (6H) and Cfos (6I), that were otherwise increased post 974 
TNF-α administration. All experiments were conducted on 3 separate occasions (n = 3), RT-PCR 975 
assays were performed in duplicate. *Significantly different vs. TNF-α. # Significantly different vs. 976 
DM. + Significantly different vs. LG.  977 
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